A Phase Ib Trial of Concurrent Cetuximab (ERBITUX) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY) in Locally Advanced Head and Neck Cancer

Trial Profile

A Phase Ib Trial of Concurrent Cetuximab (ERBITUX) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY) in Locally Advanced Head and Neck Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Cetuximab
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
    • 11 Oct 2016 Status changed from active, no longer recruiting to completed,according to the results presented at the 41st European Society for Medical Oncology Congress.
    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top